<DOC>
	<DOCNO>NCT01615887</DOCNO>
	<brief_summary>Amphetamines show improve cognition use limit due side effect . Lisdexamfetamine amphetamine pro-drug , minimize effect safely use child adult Attention Deficit Hyperactivity Disorder ( ADHD ) . The investigator hypothesize lisdexamfetamine may improve cognitive ability MS patient document cognitive dysfunction . Because lisdexamfetamine stimulant positive effect observe primarily domains process speed work memory . The investigator therefore propose study primary objective ass efficacy lisdexamfetamine improve attention process speed MS . The secondary objective ( ) assessment safety tolerability lisdexamfetamine MS population , ( b ) test effect drug cognitive domain , depression , self informant report cognitive executive function demand activity behavior .</brief_summary>
	<brief_title>Study Lisdexamfetamine Sulfate Treat Cognitive Dysfunction Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Lisdexamfetamine Dimesylate</mesh_term>
	<criteria>Males/Females ≥ 18 year old &lt; 55 year old capable understand comply protocol , include speak write fluent English least 9th grade education . Have diagnosis either Relapsing Remitting Secondary Progressive MS , per revise McDonald 's Criteria ( 68 ) . Have receive steroid last thirty ( 30 ) day relapse last ninety ( 90 ) day , whose MS consider stable . Presence cognitive dysfunction characterize slow process speed indicate score 1.5 SD age/education match norm SDMT PASAT . An Expanded Disability Status Scale ( EDSS ) ≤ 6.5 Have give write informed consent prior studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice his/her future medical care . Are capable performing requirement NP test battery include least 20/70 near visual acuity near vision chart , correction allow . If female , must neither pregnant breastfeeding must either ( ) &gt; 12 month postmenopausal surgically sterilize , ( b ) agree use acceptable method birth control duration study . Abstinence consider acceptable method birth control . Have cognitive deficit cause concomitant medication usage significant neurological/psychological disease e.g . Alzheimer 's disease , Parkinson 's disease , stroke , transient ischemic attack , Vascular Dementia , Huntington 's disease , traumatic brain injury chronic CNS infection Have evidence medical cause ( ) cognitive impairment Have evidence major depression determine positive BDIFS clinician interview Have uncontrolled labile hypertension , tachycardia , cardiovascular cerebrovascular disease Have demonstrate hypersensitivity amphetamine past The following concomitant medication permit use within 28 day enrollment study Monoamine Oxidase Inhibitors Inhaled Beta2agonists Sympathomimetics Antipsychotic agent Modafinil Tricyclic Antidepressants Anticonvulsants gabapentin pregabalin The following medication permit patient stable dose ≥ 6 week : Short act benzodiazepine , qhs administration Gabapentin pregabalin Cholinesterase inhibitor donepezil , galantamine , rivastigmine Memantine Antispasmodics Selective serotonin reuptake inhibitor serotoninnorepinephrine reuptake inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2012</verification_date>
</DOC>